Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT04312282
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Annovera™ Drug-Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- TherapeuticsMD
- Target Recruit Count
- 67
- Registration Number
- NCT04290390
- Locations
- 🇨🇦
Syneos Health, Quebec City, Quebec, Canada
A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 48
- Registration Number
- NCT04268394
- Locations
- 🇬🇧
Richmond Pharmacology Limited, London, United Kingdom
A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT04208373
- Locations
- 🇧🇪
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerpen, Belgium
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 36
- Registration Number
- NCT04166669
- Locations
- 🇳🇱
PRA-EDS, Groningen, Netherlands
🇳🇱PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen, Netherlands
A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 114
- Registration Number
- NCT04154800
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 80
- Registration Number
- NCT04142762
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04138836
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Beta Pharma, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04135833
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT04121910
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.